

Referenzen

1. Fachinformation Opdualag®, aktueller Stand.
2. Lipson EJ, Stephen Hodi F, Tawbi H, et al. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer 2025;225:115547.